Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
D003327	Coronary Disease NIH	0.41
D029424	Pulmonary Disease, Chronic Obstructive NIH	0.35
D006331	Heart Diseases NIH	0.35
D008173	Lung Diseases, Obstructive NIH	0.33
D014777	Virus Diseases NIH	0.12
D007239	Infection NIH	0.05
D045169	Severe Acute Respiratory Syndrome NIH	0.05
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (2)

	Name (Synonyms)	Correlation
HP:0006510	Chronic pulmonary obstruction HPO	0.35
HP:0006536	Pulmonary obstruction HPO	0.33

There is one clinical trial.

Clinical Trials

1 Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1

The objective of this study is to evaluate the efficacy and safety of the Unisabana-Herons invasive mechanical ventilator designed to provide the basic ventilatory support necessary to preserve the life of patients with respiratory failure and indication of mechanical ventilation, especially for those who suffer from acute respiratory distress syndrome (ARDS) when conventional commercial invasive ventilators are not available in the context of the health emergency due to the COVID-19 epidemic. The Unisabana-Herons ventilator allows to precisely configure the respiratory rate, tidal volume (or inspired air volume), inspiratory time, the inspiration: expiration ratio, the positive pressure at the end of expiration (PEEP), the inspired fraction of oxygen and inspiratory air flow, parameters that allow managing the respiratory failure associated with COVID-19. The ventilator also monitors peak inspiratory pressures (PIP), mean, PEEP, plateau, and graphs in real time the pressure-time, volume-time, flow-time curves, which allows detecting when one of these is at levels dangerous to induce ventilator trauma (barotrauma and volutrauma) and thus ensure effective and safe ventilation, so as to avoid ventilator-induced lung injury.

NCT04497623 Covid19 Device: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours

Primary Outcomes

Description: Maintenance: less than 20% drop in PaO2 with respect to the baseline measurements made in the 30 minutes before connecting the Unisabana-Herons ventilator.

Measure: Improvement or maintenance of the oxygenation level measured by PaO2

Time: 24 hours

Description: Maintenance: less than 20% drop in SatO2 levels with respect to the baseline measurements made in the 30 minutes before connecting the Unisabana-Herons ventilator.

Measure: Improvement or maintenance of the oxygenation level measured by O2 Saturation

Time: 24 hours

Secondary Outcomes

Description: Maintenance is defined as a change of less than 20% in the levels of this variable with respect to the baseline measurements made in the 30 minutes before connecting the Unisabana-Herons ventilator.

Measure: Improvement or maintenance of adequate levels of carbon dioxide measured by PaCO2

Time: 24 hours

Measure: Improvement or maintenance of adequate levels of HCO3

Time: 24 hours

Measure: Improvement or maintenance of adequate levels of excess base.

Time: 24 hours

Measure: Improvement or maintenance of adequate levels of blood pH

Time: 24 hours

Description: Stability is defined as a decrease of less than 20% in this variable with respect to the baseline measurements made in the 30 minutes before connecting the Unisabana-Herons ventilator.

Measure: Improvement or maintenance of PaO2/FiO2

Time: 24 hours

Measure: Improvement or maintenance of SatO2/FiO2

Time: 24 hours